#1
RANDOMIZED CONTROLLED TRIAL
Ruiqi Li, Xiaoxia Hu, Libing Wang, Hui Cheng, Shuqing Lv, Weiping Zhang, Jianmin Wang, Jianmin Yang, Xianmin Song
Acute myeloid leukemia (AML) patients with t(8;21) aberration often have favorable outcomes, however, relapse still occurs in 30-40% patients, with only 50-60% of patients with t(8;21) AML cured with regimens containing high-dose cytarabine (HD-Ara-C). To evaluate the effects of fludarabine and cytarabine (FA) consolidation therapy for t(8;21) AML patients, a prospective randomized study was performed. A total of 45 patients with t(8;21) AML after achieving complete remission (CR) were randomly assigned to receive four course consolidation with FA (n = 23) or HD-Ara-C (n = 22)...
January 2017: American Journal of Hematology
1